An observational study in Healthy, Lupus and Celiac, sponsored by Joined Bio. Recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Joined Bio · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.
Among the 103 studies in Celiac Disease with a site in United States, this one is the 2nd largest by planned enrollment of the 35 observational ones that give a count, is one of 5 that started in 2025, is one of 35 observational ones, reaches primary completion later than 19 of the 19 other live ones, and was the 101st registered.
353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.
Browse Celiac Disease studies →16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:
Nielsen Fernandez-Becker · Sites in United States
Ages 18+
Chugai Pharmaceutical · Sites in United States, Australia, New Zealand
Ages 18–75
Columbia University · Sites in United States
Ages 18–75
Luventix, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
University of Chicago · Sites in United States
Ages 18–75 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 22 · Phase 3 2 · Phase 4 2
First in 1995; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100,000 is above the median of 185 across 134 observational studies indexed under Celiac Disease.
Median enrollment 46 across the 68 interventional studies, 175 across the 35 observational. Of the 74 that completed or were terminated, 17 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 103 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Joined Bio as lead sponsor.
Joined Bio has 1 study filed under Celiac Disease — fewer than ten, so there is no comparison to draw.
7 of the studies in Celiac Disease with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06310291Barinthus BiotherapeuticsVTP-1000 in Adults With Celiac Disease | 2026-11 |
| NCT06908057AdventHealth Translational Research InstituteAccessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D) | 2026-12 |
| NCT05680012University of ChicagoTissue Destruction and Healing in Celiac Disease | 2027-05-01 |
| NCT07377565Nielsen Fernandez-BeckerA First-in-Patient Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease | 2027-06-01 |
| NCT07239336Chugai PharmaceuticalStudy of DONQ52 in Active Celiac Disease | 2027-06-15 |
Add all 7 to your calendar (.ics) → With an account.
Among the 103 studies in Celiac Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to help researchers better understand health conditions and develop improved tests, treatments, and cures for diseases. Joined Bio collects health data, lifestyle information, biological samples, and feedback from participants and provides this to qualified research partners.
Primary: The primary objective of this study is to connect participants with specific health profiles, along with biospecimens and associated de-identified health data, to scientific researchers who are searching for new diagnostics and treatments for a wide array of conditions. This will accelerate medical discovery by connecting medical research with the power of patient participation.
Secondary: The secondary objective of this study is to allow participants with specific health profiles, along with their de-identified health data, to help further the cause of medicine generally through interviews, surveys, and other minimal risk research activities desired by life science organizations.
Outside of this protocol, Joined Bio is creating a network of individuals who are interested in participating in research. Individuals are recruited across a broad cross-section of ages, medical conditions, and geographic locations within the United States. These individuals voluntarily join the Joined Bio network, consent to share health information with Joined, and then securely transfer their health information to Joined Bio. All health information is stored in a de-identified manner (with the exception of dates of service, which are protected in accordance with HIPAA) and encrypted with Joined Bio holding re-identification keys.
Joined Bio then searches its network of participants to see if there are matches to the research project. If there are matches, Joined Bio re-identifies the individual and reaches out to them to let them know that they match up to a research project and also to provide them with information about the research.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This is non-interventional, observational only research. Participants may be healthy. Participants will be invited to participate on a per-project basis, depending on the cohort requirements for the project.
Other: Observation
Participants may have a condition such as lupus, celiac, dermatitis or other condition. Participants will be invited to participate on a per-project basis, depending on the cohort requirements for the project.
Other: Observation
This is non-interventional, observational only
Observation for biomarker identification
There is no defined study outcome. Rather this is an observational study of multiple participant populations that hopes to identify new biomarkers, treatments and/or diagnostic applications.
Time frame: 10 years
Plan to share: No
Started Apr 2025 (actual). Primary completion is estimated for Sep 2035, 125 months after the start.
Of 48 observational studies under Celiac Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 83. This study's planned 125 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.